Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Building A New Model For Developing New Therapies: An Interview With AstraZeneca's Strategic Alliance Asia Director Richard Wang

This article was originally published in PharmAsia News

Executive Summary

Although AstraZeneca is paring down its pipeline by halting discovery efforts in 10 specific diseases, which account for 25 percent of the total diseases that earlier drove research by AstraZeneca ("The Pink Sheet" Daily, March 2, 2010), it won't stop R&D expansion plans in China. As big pharmaceutical firms compete to find the next generation of innovative drugs, translational science may help companies to find the right drug for the right patient and bring these medicines to market faster. During the recent Asia Pharma R&D Leaders conference in Shanghai, Richard Wang, AstraZeneca's Director of Strategic Alliances - Asia, sat down with PharmAsia News' Shanghai Bureau to discuss the strategy of AstraZeneca's Innovation Center China and how translational science is helping the company develop new compounds.

You may also be interested in...



Qiagen Forms JV With Shanghai's Bio-X Center For Translational Research In China

Qiagen forms JV with Shanghai Jiao Tong University for translational research to focus on biomarkers, diagnostics for developing drugs specifically for Asians.

MNCs Need China-Oriented Oncology Strategy Mixed With Pricing Know-how

To succeed in China's fast-growing oncology market, multinational pharma companies need to look closely at their product mix and figure out whether getting listed on the country's reimbursed drug list will increase volume enough to offset price reductions, or whether it makes more sense to charge full retail prices to patients paying out-of-pocket and settle for lower volume

MNCs Need China-Oriented Oncology Strategy Mixed With Pricing Know-how

To succeed in China's fast-growing oncology market, multinational pharma companies need to look closely at their product mix and figure out whether getting listed on the country's reimbursed drug list will increase volume enough to offset price reductions, or whether it makes more sense to charge full retail prices to patients paying out-of-pocket and settle for lower volume

Related Content

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel